Abstract: This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject.
Type:
Application
Filed:
June 15, 2017
Publication date:
November 16, 2017
Applicant:
SARAH HERZOG MEMORIAL HOSPITAL-EZRATH NASHIM
Abstract: This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject.
Type:
Grant
Filed:
May 26, 2014
Date of Patent:
June 27, 2017
Assignee:
SARAH HERZOG MEMORIAL HOSPITAL-EZRATH NASHIM
Abstract: This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject.
Type:
Application
Filed:
May 26, 2014
Publication date:
May 5, 2016
Applicant:
SARAH HERZOG MEMORIAL HOSPITAL-EZRATH NASHIM
Abstract: A pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
January 2, 2014
Date of Patent:
March 1, 2016
Assignee:
Sarah Herzog Memorial Hospital Ezrath Nashim Association
Abstract: A pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
January 2, 2014
Date of Patent:
May 12, 2015
Assignee:
Sarah Herzog Memorial Hospital Ezrath Nashim Association
Abstract: A pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.
Type:
Application
Filed:
January 2, 2014
Publication date:
July 3, 2014
Applicant:
Sarah Herzog Memorial Hospital Ezrath Nashim Association
Abstract: The invention provides a pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.
Type:
Application
Filed:
January 2, 2014
Publication date:
May 1, 2014
Applicant:
Sarah Herzog Memorial Hospital Ezrath Nashim Association